Analysts Set Kenvue Inc. (NYSE:KVUE) Price Target at $25.33

Kenvue Inc. (NYSE:KVUE - Get Free Report) has been given a consensus recommendation of "Hold" by the twelve brokerages that are covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $24.88.

A number of equities research analysts have recently commented on the stock. Citigroup reduced their price objective on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research note on Tuesday. Bank of America cut their target price on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday. Redburn Atlantic started coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price on the stock. Barclays lowered their price objective on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Tuesday. Finally, UBS Group upped their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Friday, May 9th.

Institutional Trading of Kenvue

Large investors have recently added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. boosted its position in Kenvue by 4.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock worth $2,545,000 after purchasing an additional 4,034 shares during the period. Starboard Value LP bought a new stake in Kenvue during the fourth quarter valued at approximately $467,864,000. TrueMark Investments LLC lifted its position in Kenvue by 9.3% during the fourth quarter. TrueMark Investments LLC now owns 190,595 shares of the company's stock valued at $4,069,000 after purchasing an additional 16,161 shares during the last quarter. Kingswood Wealth Advisors LLC bought a new stake in Kenvue during the first quarter valued at approximately $413,000. Finally, DLK Investment Management LLC bought a new stake in Kenvue during the first quarter valued at approximately $4,100,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Trading Up 2.1%

NYSE KVUE traded up $0.46 on Friday, hitting $21.85. The company's stock had a trading volume of 21,829,077 shares, compared to its average volume of 16,329,336. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63. Kenvue has a 1-year low of $17.85 and a 1-year high of $25.17. The company's 50-day moving average is $22.26 and its 200 day moving average is $22.29. The firm has a market cap of $41.91 billion, a PE ratio of 39.72, a PEG ratio of 3.39 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The firm had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. During the same period in the prior year, the company posted $0.28 EPS. The company's revenue was down 3.9% on a year-over-year basis. As a group, analysts predict that Kenvue will post 1.14 earnings per share for the current fiscal year.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.